Literature DB >> 19396149

Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas.

G Martignoni1, M Pea, S Gobbo, M Brunelli, F Bonetti, D Segala, Chin-Chen Pan, G Netto, C Doglioni, O Hes, P Argani, M Chilosi.   

Abstract

The microphthalmia transcription factor/transcription factor E (TFE)-family translocation renal cell carcinomas bear specific translocations that result in overexpression of TFE3 or TFEB. TFE3 fusion gene product overexpression occurs as consequence of different translocations involving chromosome Xp11.2, whereas TFEB overexpression is the result of the specific translocation t(6;11)(p21;q12), which fuses the Alpha gene to TFEB. Both TFE3 and TFEB are closely related members of the microphthalmia transcription factor/TFE-family, which also includes TFEC and microphthalmia transcription factor. These transcription factors have overlapping transcriptional targets. Overexpression of microphthalmia transcription factor has been shown to mediate the expression of cathepsin-K in osteoclasts. We hypothesize that the overexpression of the related TFE3 fusion proteins and TFEB in translocation renal cell carcinomas may have the same effect. We studied cathepsin-K in 17 cytogenetically confirmed microphthalmia transcription factor/TFE-family translocation renal cell carcinomas. Seven cases showed a t(6;11)(p21;q12), ten cases showed translocations involving Xp11.2; five cases t(X;1)(p11;q21) resulting in a PRCC-TFE3 gene fusion; three cases t(X;1)(p11;p34) resulting in a PSF-TFE3 gene fusion, one t(X;17)(p11;q25) resulting in an ASPL-TFE3 gene fusion, and one t(X;3)(p11;q23) with an unknown TFE3 gene fusion. As control we analyzed cathepsin-K in 210 clear cell, 40 papillary, 25 chromophobe renal cell carcinomas and 30 oncocytomas. All seven TFEB translocation renal cell carcinomas were labeled for cathepsin-K. Among the cytogenetically confirmed TFE3 translocation renal cell carcinomas, 6 out of 10 were positive. None of the other renal neoplasms expressed cathepsin-K. We conclude the following: (1) cathepsin-K is consistently and strongly expressed in TFEB translocation renal cell carcinomas and in 6 of 10 TFE3 translocation renal cell carcinomas. (2) Cathepsin-K immunolabeling in both TFE3 and TFEB translocation renal cell carcinomas distinguishes these neoplasms from the more common adult renal cell carcinomas, and may be a specific marker of these neoplasms. (3) These results further support the concept that the overexpression of TFE3 or TFEB in these neoplasms activates the expression of genes normally regulated by microphthalmia transcription factor in other cell types.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19396149     DOI: 10.1038/modpathol.2009.58

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  40 in total

Review 1.  Diagnostic approach to eosinophilic renal neoplasms.

Authors:  Oleksandr N Kryvenko; Merce Jorda; Pedram Argani; Jonathan I Epstein
Journal:  Arch Pathol Lab Med       Date:  2014-11       Impact factor: 5.534

2.  Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers.

Authors:  Pedram Argani; Jessica Hicks; Angelo M De Marzo; Roula Albadine; Peter B Illei; Marc Ladanyi; Victor E Reuter; George J Netto
Journal:  Am J Surg Pathol       Date:  2010-09       Impact factor: 6.394

3.  [Histopathology of renal cell carcinoma].

Authors:  C G Stöhr; K Amann; A Hartmann
Journal:  Urologe A       Date:  2013-07       Impact factor: 0.639

Review 4.  MiT family translocation renal cell carcinomas: A 15th anniversary update.

Authors:  Jatin S Gandhi; Faizan Malik; Mahul B Amin; Pedram Argani; Armita Bahrami
Journal:  Histol Histopathol       Date:  2019-09-06       Impact factor: 2.303

5.  Cathepsin K expression in clear cell "sugar" tumor (PEComa) of the lung.

Authors:  Anna Caliò; Maria Cecilia Mengoli; Alberto Cavazza; Giulio Rossi; Claudio Ghimenton; Matteo Brunelli; Maurizio Pea; Marco Chilosi; Lisa Marcolini; Guido Martignoni
Journal:  Virchows Arch       Date:  2018-03-07       Impact factor: 4.064

6.  t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of 10 new genetically confirmed cases.

Authors:  Nathaniel E Smith; Peter B Illei; Mohamed Allaf; Nilda Gonzalez; Kerry Morris; Jessica Hicks; Angelo Demarzo; Victor E Reuter; Mahul B Amin; Jonathan I Epstein; George J Netto; Pedram Argani
Journal:  Am J Surg Pathol       Date:  2014-05       Impact factor: 6.394

7.  TFEB-amplified Renal Cell Carcinomas: An Aggressive Molecular Subset Demonstrating Variable Melanocytic Marker Expression and Morphologic Heterogeneity.

Authors:  Pedram Argani; Victor E Reuter; Lei Zhang; Yun-Shao Sung; Yi Ning; Jonathan I Epstein; George J Netto; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-11       Impact factor: 6.394

Review 8.  [The translocation carcinoma: A pediatric renal tumor also in adults].

Authors:  E Bruder; H Moch
Journal:  Pathologe       Date:  2016-03       Impact factor: 1.011

9.  TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.

Authors:  Pedram Argani; Minghao Zhong; Victor E Reuter; John T Fallon; Jonathan I Epstein; George J Netto; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2016-06       Impact factor: 6.394

Review 10.  Renal cell carcinoma: Evolving and emerging subtypes.

Authors:  Suzanne M Crumley; Mukul Divatia; Luan Truong; Steven Shen; Alberto G Ayala; Jae Y Ro
Journal:  World J Clin Cases       Date:  2013-12-16       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.